Inivata Wins One Nucleus BioNewsRound Award 2016 at Genesis Conference

December 5, 2016

Inivata Wins One Nucleus BioNewsRound Award 2016 at Genesis Conference

5 December, 2016 – Cambridge, UK – Inivata has been named as this year’s winner of the One Nucleus BioNewsRound Award, as announced at the Genesis 2016 in London.  The award reflects an online vote from peers following the selection of a six-strong shortlist by an expert panel.  Inivata was recognised for the announcement of its £31.5m Series A fundraising round to accelerate clinical studies of its ctDNA liquid biopsy technology.

Inivata uses a simple blood test, known as a liquid biopsy, to detect and analyse circulating tumour DNA (ctDNA) through an exclusive bioinformatics technology.  Inivata’s revolutionary approach, called InVision®, uses Next-Generation Sequencing along with an amplification process prior to sequencing and advanced, proprietary analytical methods enable the separation of true cancer mutations from background noise.  Inivata was founded in late 2014 from the Nitzan Rosenfeld Lab and draws on world-class, academic research from the University of Cambridge and Cancer Research UK.

“Inivata is honoured to receive the BioNewsAward 2016 and the recognition of our peers throughout the UK and further afield.  We look forward to further significant developments and announcements as we continue to advance the clinical validation of our technology and ultimately to play a part in revolutionising cancer testing and treatment and improving patient outcomes,” said Michael Stocum, CEO of Inivata.

Chief Executive of One Nucleus, Harriet Fear explains, “The BioNewsRound award is much coveted and Inivata is an incredibly worthy winner.  The criteria is to showcase how the ‘news’ has impacted on the company, the sector, and of course ultimately has impacted or will impact on patients.  The award was incredibly close.   Importantly it is peer reviewed as the vote goes out to the sector.  We had over 1000 respond so the award is genuinely peer respected and appreciated – and a fantastic coup for Inivata – much deserved’.

About Inivata

Inivata, a clinical cancer genomics company, is employing the precision of ctDNA analysis to improve personalized healthcare in oncology. Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata’s proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata’s Invision® ctDNA assay provides a highly sensitive analysis of a highly-select gene panel to identify actionable mutations for oncologists to treat their patients optimally. In 2016, Inivata opened a CLIA lab in Research Triangle Park, NC and launched a large-scale, prospective clinical validation study of the Company’s ctDNA analysis in lung cancer. For more information and a full listing of investors, please go to www.inivata.com. Follow us on Twitter @Inivata.

 

Media Contacts:

Liz Macfadyen

Liz.macfadyen@inivata.com

+44 (0)7739462323

 

Consilium Strategic Communications

Chris Gardner/Laura Thornton

Email: inivata@consilium-comms.com

Phone: +44 (0)20 3709 5700

 

One Nucleus

Harriet Fear

Email: harriet@onenucleus.com

 

About One Nucleus

One Nucleus is an international membership organisation for life science and healthcare companies. We are based in Cambridge with the majority of our members across the Cambridge/London corridor – at the heart of Europe’s largest life science and healthcare cluster.
Organisation History

Established in 1997, One Nucleus is a not-for-profit membership organisation, located in Cambridge UK.

We have over 470 organisations as members, including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus’ mission is to maximise the global competitiveness of our members.  For our science and technology-based members, that means them being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For our business and professional services members, it means them delivering exceptional services that significantly enhance the business performance of their clients.

 

About the Genesis BioNewsRound Award

Genesis is One Nucleus’ international networking conference that takes place every December for over 800 delegates.

One Nucleus runs a BioNewsRound Award twice yearly – in the Summer at our ON Helix translational research conference and at Genesis in London in December. The Award showcases the best of the industry and asks for entrants to submit an announcement or piece of PR publicised within the past 12 months. A short list of finalists is announced, having been selected by a panel of investors and analysts and the process then moves on to an online voting system where the sector decides the winner.

 

Websites: www.inivata.com and www.onenucleus.com and www.genesisconference.com

Discover more news